U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940388) titled 'Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.' on April 01.
Brief Summary: This prospective, multi-center, phase II randomized controlled trial will evaluate the actual benefit of adding immunotherapy with tislelizumab to the currently most effective approach against LARC, namely TNT. In this trial, we will harness several elements that may each potentially contribute to an overall high efficacy, at least in local outcomes: nCRT rather than SCRT, full length (8 cycles of mFOLFOX6) of consolidation chemotherapy, CIMT following nCRT (exploiting the upregulation of the immune response ind...